Q3 2020 Sales Performance
Zejula: strong label and commercial execution drive
share in 1LM OC
Best-in-class PARPI; opportunity for growth
£92m in Q3, +47%; positive CHMP opinion for PRIMA
■ 1st PARP inhibitor to show PFS1 in first line ovarian
cancer regardless of biomarker status
Supportive guidelines from NCCN and ASCO
■ Watch & wait
approach still
100%
9016
11%
gsk
Increasing new patients starts in 1LM OC
90
80
70
60
50
40
30
20
10
75%
!!!
5%
80%
43%
70%
70%
80%
used in >70% of
50%
40%
30%
OC setting in the
US2
10%
20%
41%
9%
10%
14%
0%
All Patients
BRCAmut
BRCAwt
women in 1LM
18%
1LM New OC Patients on PARP14
24/07/2020
07/08/2020
21/08/2020
12/06/2020
26/06/2020
10/07/2020
03/04/2020
17/04/2020
01/05/2020
15/05/2020
29/05/2020
20/03/2020
Lynparza
Zejula
Rubraca
PARPI ■PARPI+ Bevacizumab Bevacizumab W&W Other
ZEAL-1L study in NSCLC to start shortly; demonstrated
tumour penetration and ability to cross the blood brain
barrier³
46% of new 1LM
patients getting a
PARPI now
receive Zejula 5
31% of all
PARPI patients
(new and repeat)
now on Zejula in 1LM6
4. Symphony Claims Data through August 2020 - Rolling 3 Week Average
5. Symphony Health Aug 2020
6. Flatiron Health Aug 2020
1 PFS = Progression-free survival
2. Flatiron Health Jul 2020
3. Sun et al. Oncotarget 2018, Vol 9 (no 98)
34
=4View entire presentation